<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851849</url>
  </required_header>
  <id_info>
    <org_study_id>L6972-04</org_study_id>
    <nct_id>NCT02851849</nct_id>
  </id_info>
  <brief_title>A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ligand Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c)&#xD;
      during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects&#xD;
      with Type 2 Diabetes Mellitus (T2DM)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 12-week, randomized, double-blind, placebo-controlled, 4-arm, parallel group,&#xD;
      multi-center study to evaluate the safety and efficacy of LGD-6972 in subjects with T2DM&#xD;
      inadequately controlled on metformin monotherapy (a stable [≥12 weeks], daily dose of ≥1000mg&#xD;
      at randomization). Subjects with T2DM will be treated with one of 3 dose levels of LGD-6972&#xD;
      (5 mg, 10 mg, or 15 mg) or placebo once daily (QD) for 12 weeks. Randomization will be&#xD;
      stratified by HbAlc ≤8.5% or &gt;8.5% at the Placebo Lead-in Visit.&#xD;
&#xD;
      Qualified subjects who require adjustment or stabilization of their metformin dose will&#xD;
      participate in a run-in period of up to 12 additional weeks prior to randomization. Subjects&#xD;
      will have the option to participate in an oral glucose tolerance test (OGTT) at baseline and&#xD;
      end of treatment for assessment of exploratory endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1C</measure>
    <time_frame>Baseline to Weeks 2,4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting glucose</measure>
    <time_frame>Baseline to Weeks 2,4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for fasting glucagon</measure>
    <time_frame>Baseline to Weeks 2,4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for fasting GLP-1 (total and active)</measure>
    <time_frame>Baseline to Weeks 2,4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for fasting insulin</measure>
    <time_frame>Baseline to Weeks 2,4,8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for fasting lipids (total, LDL, and HDL cholesterol and triglycerides)</measure>
    <time_frame>Baseline to Weeks 2,4,8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure (systolic and diastolic)</measure>
    <time_frame>Baseline to Weeks 2,4,8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline to Weeks 2,4,8 and 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LGD-6972-5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg LGD-6972 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGD-6972-10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg LGD-6972 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGD-6972-15 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg LGD-6972 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGD-6972-5 mg</intervention_name>
    <description>5 mg LGD-6972 QD</description>
    <arm_group_label>LGD-6972-5 mg</arm_group_label>
    <other_name>LGD-6972 sodium salt capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGD-6972-10 mg</intervention_name>
    <description>10 mg LGD-6972 QD</description>
    <arm_group_label>LGD-6972-10 mg</arm_group_label>
    <other_name>LGD-6972 sodium salt capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGD-6972-15 mg</intervention_name>
    <description>15 mg LGD-6972 QD</description>
    <arm_group_label>LGD-6972-15 mg</arm_group_label>
    <other_name>LGD-6972 sodium salt capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects must be surgically sterile (hysterectomy or bilateral oophorectomy or&#xD;
             bilateral tubal ligation), or naturally post-menopausal for at least 12 months and&#xD;
             with a follicle stimulating hormone (FSH) level in the post-menopausal range (if not&#xD;
             taking hormone replacement therapy)&#xD;
&#xD;
          2. Male subjects must either have a vasectomy or agree that they and any female partners&#xD;
             will use 2 acceptable forms of contraception, one of which must be a condom, until 30&#xD;
             days after the last dose of study drug. Other acceptable forms of contraception&#xD;
             include hormonal contraceptives that have been at stable dose for 12 weeks prior to&#xD;
             randomization, intrauterine device, Depo-Provera®, Norplant® System Implants,&#xD;
             bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive&#xD;
             sponge, foam, or jelly. Also, male subjects must not donate sperm during the study and&#xD;
             for 30 days after the last dose of study drug&#xD;
&#xD;
          3. Willing and able to provide written informed consent&#xD;
&#xD;
          4. Diagnosis of T2DM according to American Diabetes Association criteria&#xD;
&#xD;
          5. Currently on stable metformin or metformin extended-release therapy (unchanged dose&#xD;
             [minimum daily dose of 1000 mg] for ≥12 weeks prior to screening)&#xD;
&#xD;
          6. Subjects must have an HbA1c value of ≥7.0% to ≤10.5%&#xD;
&#xD;
          7. Subjects must have a fasting plasma glucose of ≤260 mg/dL&#xD;
&#xD;
          8. Subjects must have a body mass index (BMI) between 25 kg/m2 and 40 kg/m2, inclusive,&#xD;
             and must weigh more than 45 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent&#xD;
             hypoglycemia or hypoglycemia unawareness&#xD;
&#xD;
          2. Women of childbearing potential, lactating, or has a positive pregnancy test&#xD;
&#xD;
          3. History or presence of alcoholism or drug abuse within 2 years prior to screening&#xD;
&#xD;
          4. Unwilling to comply with study restrictions, including restrictions on strenuous&#xD;
             exercise&#xD;
&#xD;
          5. Presence of any of the following conditions: renal impairment (defined as history or&#xD;
             estimated glomerular filtration rate at screening of &lt;45 mL/min using the Modification&#xD;
             of Diet in Renal Disease equation), diabetic proliferative retinopathy, severely&#xD;
             symptomatic diabetic neuropathy requiring treatment, diabetic gastroparesis, active&#xD;
             liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis,&#xD;
             symptomatic gall bladder disease, or pancreatitis&#xD;
&#xD;
          6. Serum triglyceride level &gt; 400 mg/dL at screening&#xD;
&#xD;
          7. Liver transaminase levels (AST or ALT) &gt;150% ULN, total bilirubin &gt;2 ULN, or creatine&#xD;
             kinase (CK) levels &gt; 3 × ULN at screening&#xD;
&#xD;
          8. History or evidence of clinically significant cardiovascular, pulmonary, renal,&#xD;
             endocrine (other than T2DM), hepatic, neurologic, psychiatric, immunologic,&#xD;
             hematologic, gastrointestinal, or metabolic disease or surgical intervention (eg,&#xD;
             bariatric surgery) or allergic conditions (including drug allergies, but excluding&#xD;
             untreated, asymptomatic, seasonal allergies at time of dosing)&#xD;
&#xD;
          9. Myocardial infarction, unstable angina, arterial revascularization, stroke,&#xD;
             symptomatic peripheral artery disease, deep vein thrombosis, New York Heart&#xD;
             Association Functional Class III or IV heart failure, or transient ischemic attack&#xD;
             within 6 months prior to screening&#xD;
&#xD;
         10. History of malignant hypertension or a recent history of uncontrolled high blood&#xD;
             pressure or at screening has a seated systolic blood pressure &gt;160 mmHg and/or&#xD;
             diastolic blood pressure &gt;100 mmHg after at least a 5 minute rest. Blood pressure is&#xD;
             determined as the mean of triplicate measurements collected at 2- minute intervals&#xD;
             after the subject has been sitting quietly for at least 5 minutes. Therapy for&#xD;
             hypertension (beta blockers excluded) that has been stable for at least 8 weeks prior&#xD;
             to screening is permitted&#xD;
&#xD;
         11. Arm size in excess of the maximum limit of the largest cuff provided with the study&#xD;
             blood pressure monitor&#xD;
&#xD;
         12. History of malignancy (except adequately treated basal or squamous cell skin cancer or&#xD;
             cervical carcinoma in situ) within 5 years prior to screening&#xD;
&#xD;
         13. History or evidence of QT prolongation or clinically significant QT prolongation (QTcF&#xD;
             &gt;450 msec) at screening, or other significant ECG findings at screening that may place&#xD;
             the subject at increased risk by participating in the study&#xD;
&#xD;
         14. Treatment with any type of insulin (injected or inhaled) for &gt; 6 consecutive days&#xD;
             within 6 months prior to screening or any insulin therapy within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
         15. Treated with peroxisome proliferator-activated receptor-gamma agonists&#xD;
             (thiazolidinediones [TZDs]), incretin therapy (GLP-1 agonists). or amylin mimetics&#xD;
             within 12 weeks prior to screening&#xD;
&#xD;
         16. Taking any of the following prohibited medications&#xD;
&#xD;
               -  Antidepressants, antipsychotics, anti-epileptics, hormone replacement therapies&#xD;
                  (estrogen, progestin), testosterone therapies, and thyroid replacement&#xD;
                  medications that are not at a stable dose for at least 12 weeks prior to&#xD;
                  screening&#xD;
&#xD;
               -  Lipid-modifying medications and anti-hypertensive medications that have not been&#xD;
                  at a stable dose for at least 8 weeks prior to the Screening Visit (excluding&#xD;
                  bile acid sequestrants, ezetimibe, and beta blockers, which are prohibited&#xD;
&#xD;
               -  Over-the-counter herbal medications and supplement (aside from once daily&#xD;
                  multivitamins)&#xD;
&#xD;
         17. Treatment with systemic corticosteroids, which must be discontinued at least 4 weeks&#xD;
             prior to screening. Note: Inhaled, intraarticular, intranasal and topical&#xD;
             corticosteroids are permitted&#xD;
&#xD;
         18. Currently treated with weight-loss medications. These must be discontinued ≥12 weeks&#xD;
             prior to screening&#xD;
&#xD;
         19. History or evidence of intravenous illicit drug use, active hepatitis B virus (HBV),&#xD;
             hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         20. Known hypersensitivity or idiosyncratic reaction to glucagon receptor (GCGR)&#xD;
             antagonists or LGD-6972&#xD;
&#xD;
         21. Participation in another interventional clinical trial within 30 days prior to dosing&#xD;
             or treatment with an investigational product with 14 days or 5 half-lives of the&#xD;
             Screening Visit (whichever is longer)&#xD;
&#xD;
         22. Donated ≥ 450 mL of blood within 56 days of screening or has donated blood products&#xD;
             within 30 days of screening&#xD;
&#xD;
         23. Inability to comply with study procedures or to adhere to study-required restrictions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Marschke, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ligand Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <zip>35674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

